Randomised trialomania? The multicentre liver transplant trials of tacrolimus

The Lancet

Volumn 346, Issue 8986, 1995, Pages 1346-1350

  Starzl, T E ^a   Fung, J J ^a   McMichael, J P ^a   Todo, S ^a   Donner, A ^b   Eliasziw, M ^b   Stitt, L ^b   Meier, P ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TACROLIMUS;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GRAFT REJECTION; HUMAN; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; META ANALYSIS; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0028810729     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(95)92349-7     Document Type: Article

References (28)

1. FK 506 for human liver, kidney, and pancreas transplantation
2. Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK 506
3. Liver, kidney, and thoracic organ transplantation under FK 506
4. Kidney transplantation under FK 506
5. Evolution of liver transplantation
6. Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression
7. The reversal of rejection in human renal homografts with subsequent development of homograft tolerance
8. Cyclophosphamide and whole organ transplantation in human beings
9. The use of cyclosporin A and prednisone in cadaver kidney transplantation
10. Cyclosporin A initially as the only immunosuppressants in 34 recipients of cadaveric organs; 32 kidneys, 2 pancreases, and 2 livers
11. Conversion of liver allograft recipients from cyclosporine to FK506-based immunosuppression: benefits and pitfalls
12. Selected topics on FK 506: with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs", side effects, mechanisms, and practical pharmacokinetics
13. Variable convalescence and therapy after cadaveric renal transplantation under cyclosporin A and steroids
14. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine
15. Effect of hepatic dysfunction and T-tube clamping on FK 506 pharmacokinetics and trough concentrations
16. The effect of graft function on FK506 plasma levels, doses, and renal function, with particular reference to the liver
17. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection
18. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation
19. Nonparametric estimation from incomplete observations
20. Immunosuppression in liver transplantation
21. a proposal for structured reporting of randomized controlled trials
22. The Nazi hypothermia experiments and unethical research today
23. The continuing unethical use of placebo controls
24. Protecting the patient's interest